Effect of glicentin on gut mucosal growth in rats with jejunal and ileal Thiry-Vella fistulas.
OBJECTIVE
Glicentin stimulates growth of normal and atrophic small bowel mucosa; the mechanisms for this trophic effect of glicentin are not completely known. The purpose of this study was to determine whether the trophic effect of glicentin is mediated by mechanism involving luminal or nonluminal factors and determine whether glicentin exerts a differential trophic effect on either jejunal or ileal mucosa.


METHODS
Thirty-two male Wistar rats underwent construction of either a jejunal or ileal Thiry-Vella fistula (TVF). After 10 days recovery period, rats were further subdivided into groups to receive either saline (control) or glicentin (100 microg/kg/d). Rats were killed on day 8, and TVF as well as corresponding segments of intact jejunum or ileum were removed. Mucosa was scraped, weighed, and analyzed for protein content and Alp activity. In addition, representative sections of full-thickness bowel from each group were examined histologically.


RESULTS
In the jejunal TVF group, glicentin increased mucosal growth measurements in both the TVF and the intact jejunum. However, in the ileal TVF group, glicentin stimulated proliferation of intact ileal mucosa only; it had no effect on ileal mucosa in the TVF.


CONCLUSIONS
These results suggest that glicentin exerts a systemic effect independent of luminal factors on the proliferation of proximal gut mucosa in addition to an indirect effect produced by stimulation of endogenous luminal secretions. In contrast, an indirect mechanism appears to be the predominant action of glicentin on growth of distal gut mucosa.
Hashimoto
Naoki
N
Kinki University, School of Medicine, Department of Second Surgery, and the Nisshin Kyourin Research Center, Osaka, Japan.
Ohyanagi
Harumasa
H
Kazuyuki
Sasaki
S
D000714:Anastomosis, Surgical; D000818:Animals; D053771:Glicentin; D005934:Glucagon / Q000008:administration & dosage / Q000494:pharmacology*; D004763:Glucagon-Like Peptides; D007081:Ileostomy; D007082:Ileum / Q000187:drug effects / Q000473:pathology / Q000601:surgery; D007279:Injections, Subcutaneous; D007413:Intestinal Mucosa / Q000187:drug effects* / Q000473:pathology; D007582:Jejunostomy; D007583:Jejunum / Q000187:drug effects / Q000473:pathology / Q000601:surgery; D008297:Male; D009929:Organ Size / Q000187:drug effects; D009928:Organ Specificity; D010446:Peptide Fragments / Q000008:administration & dosage / Q000494:pharmacology*; D011498:Protein Precursors / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar
D010446:Peptide Fragments; D011498:Protein Precursors; D004763:Glucagon-Like Peptides; D053771:Glicentin; D005934:Glucagon